These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt||2011-000572-33||Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme||2015-05-08||not-yet-due|
|Exempt||2011-000765-12||Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer||2015-05-30||not-yet-due|
|Exempt||2011-000948-18||Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers||2015-05-30||not-yet-due|
|Not reported||2015-001119-11||A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer||2018-05-16||due-trials|